Drug Profile
AAMP 1
Latest Information Update: 29 Apr 2008
Price :
$50
*
At a glance
- Originator National Institutes of Health (USA)
- Class Anticoagulants; Proteins
- Mechanism of Action Heparin modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Haematological disorders
Most Recent Events
- 23 Sep 1998 No-Development-Reported for Haematological disorders in USA (Parenteral)
- 05 Jul 1996 New profile
- 05 Jul 1996 Preclinical development for Haematological disorders in USA (Parenteral)